Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial.
A chemotherapy regimen achieves unusually high remission rates in a subset of acute leukemia with specific genetic mutations, offering hope for this favorable-risk group.
Prospective multicenter Phase II trial (n=61, NCT04415008, median follow-up 32 months) established that HAD induction in CEBPAdm AML achieves exceptional CR rates and durable survival, meeting prespecified endpoints. CEBPA double mutation represents ~6–10% of AML; prior HHT-based retrospective data are now prospectively confirmed at multiple Chinese haematology centres, supporting HAD as a preferred regimen in this favorable-risk subset.
What the study was
- Study design
- Prospective multicenter single-arm Phase II trial
- Category
- Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
- Maturity
- Validated
- Journal
- Cancer Pathog Ther
Why it surfaced
First prospective multicenter Phase II trial confirming HHT-based induction in a specific AML molecular subtype (CEBPAdm); PMC full text available; enrolling from 9 Chinese tertiary centres; primary outcomes met. Novelty point: HHT mechanism specifically suppresses CEBPA expression, providing mechanistic rationale for the observed benefit.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.